TYRA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 6.68%, SMA50 14.78%, SMA200 95.96%). The stock’s 14-day RSI is 60.93 (firm momentum), while the ATR of 2.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.08% below its high and over 416.82% above its low. Average 10-day trading volume of 1.05 million shares is slightly above the 3-month average of 792.21 thousand, indicating heightened recent market interest.

Tyra Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.20. This means the shares are trading above this model’s fair value.

Tyra Biosciences, Inc. generated EPS of -$1.88 over the past year. Five-year average earnings growth is -73.69%. Wall Street analysts project EPS growth of -17.13% annually over the next five years. The latest quarter delivered EPS of -$0.50. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$41.89. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $59.00 to $30.00. The high target offers 60.72% upside. The low target suggests -18.28% downside. The mean target is $42.50. This offers 15.77% upside. Tyra Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 0.11%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 2.5% in November 07, 2024.

Tyra Biosciences, Inc. has 53.30 million shares outstanding. The public float is 17.22 million shares, elevated short interest at 16.27% of float. This equals 5.92 million shares. The short ratio is 27.5 days. Institutional investors hold 108.16% of the float. Insiders own 3.19%. RA CAPITAL MANAGEMENT, L.P. holds 10.26 million shares, Boxer Capital, LLC has 6.45 million shares and Alta Partners NextGen Fund II Management, LLC has 4.08 million shares. Over the past six months, insider transactions show net selling. They sold 510.19 thousand shares across 10 transactions.

Tyra Biosciences, Inc. (NASDAQ:TYRA) closed at $36.71 USD, gaining $0.40 (1.09%) from the previous close of $36.31. The stock is currently mid-range between its 52-week high and low $6.42 and $39.15. With a market capitalization of about $1.97 billion, Tyra Biosciences, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 911.95 thousand shares, in line with its 52-week average. Headquartered in Carlsbad, CA, Tyra Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Todd Harris, the company employs approximately 60 people and listed since September 15, 2021. Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.

Our AI price prediction model suggests that Tyra Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.2%, with price expected at $39.72 by April 07, 2026, within a range of $38.55 to $41.00 3-Month Outlook: Projected fall of -13.48%, reaching $31.76 by June 22, 2026, with a range of $30.10 to $33.39. 1-Year Outlook: Projected gain of 6.07%, with price at $38.94 by March 24, 2027, within a range of $37.13 to $40.83.

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares are up 12.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tyra Biosciences, Inc. trading at a premium to the broader market with a P/E of -18.46. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $30.06, suggesting -18.11% downside. Our AI forecast model points to short-term strength (8.2% over two weeks), a medium-term fall (-13.48% over three months), and a longer-term gain (6.07% over one year), with expected trading ranges indicating moderate volatility.

Tyra Biosciences, Inc. trades at a P/E ratio of -18.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.54 trading at moderately above to book value. The P/FCF stands at -20.94, also below market averages.